AG
VERV

Algert Global’s Verve Therapeutics VERV Stock Holding History

Algert Global’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,185
Closed -$361K – 1354
2025
Q2 		$361K Sell
32,185
-96,730
-75% -$551K 0.01% 1000
2025
Q1 		$589K Sell
128,915
-59,090
-31% -$396K 0.01% 873
2024
Q4 		$1.06M Sell
188,005
-36,211
-16% -$204K 0.02% 772
2024
Q3 		$1.08M Buy
224,216
+86,720
+63% +$504K 0.03% 733
2024
Q2 		$671K Buy
+137,496
New +$864K 0.02% 795
2024
Q1 		– Sell
-10,452
Closed -$146K – 1284
2023
Q4 		$146K Sell
10,452
-7,570
-42% -$93.8K 0.01% 1046
2023
Q3 		$239K Hold
18,022
– – 0.01% 932
2023
Q2 		$338K Buy
18,022
+7,390
+70% +$123K 0.01% 887
2023
Q1 		$153K Sell
10,632
-5,538
-34% -$108K 0.01% 1047
2022
Q4 		$313K Buy
+16,170
New +$428K 0.02% 926

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Algert Global's VERV Position: Q3 2025 in Review

Algert Global sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 32,185 shares — an estimated $361K sold.

Algert Global first reported a position in VERV in Q4 2022 and held it in 10 quarters. The position peaked at $1.08M in Q3 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Algert Global reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 32,185 Verve Therapeutics shares in Q3 2025, an estimated $361K.
  • Algert Global first reported a position in Verve Therapeutics in Q4 2022 and held it in 10 quarters.
  • Algert Global's Verve Therapeutics position peaked at $1.08M in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.